Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1616 1623 1639 1643 1645 1646 1653 1654
This examiner grants 21% of resolved cases
Sue Xu Liu examines applications in Tech Center 1600 and Art Unit 1616, where they have handled 239 resolved cases. The allowance rate of 20.9 percent indicates a challenging environment for applicants, as a significant majority of cases do not result in a grant. However, the interview lift of 18.6 percent suggests that engaging in a dialogue with the examiner can increase the chances of success compared to the baseline rate.
The prosecution process is relatively lengthy, with a median of 1614 days to allowance. This 1614-day figure reflects the time often required to overcome rejections in this art unit. Practitioners should prepare for a rigorous examination process, given that the 20.9 percent allowance rate is notably low. The 18.6 percent interview lift should be viewed as a vital tactic for navigating these difficulties.
With 239 resolved cases, the examiner's statistics are well-defined. The 1614-day median to allowance serves as a critical planning metric for stakeholders. Because the allowance rate is 20.9 percent, applicants must be precise in their claim drafting and proactive in using interviews to leverage the 18.6 percent lift.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18444007 | SOLID ACID/ANIONIC ANTIMICROBIAL AND VIRUCIDAL COMPOSITIONS AND USES THEREOF | Non-Final OA | ECOLAB USA INC. |
| 18555070 | RETINOL FORMULATION (II) | Non-Final OA | DSM IP ASSETS B.V. |
| 17814198 | T CELLS EXPRESSING MEMBRANE-ANCHORED IL-12 FOR THE TREATMENT OF CANCER | Non-Final OA | Board of Regents, The University of Texas System |
| 18134993 | COMPOSITIONS INCLUDING ENDOPHYTES FOR IMPROVING PLANT NUTRITION, GROWTH,AND PERFORMANCE AND METHODS OF USING THE SAME | Non-Final OA | University of Washington |
| 18569346 | PHARMACEUTICAL FORMULATION CONTAINING AN ANTI-IgE ANTIBODY | Non-Final OA | NOVARTIS AG |
| 18292078 | MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCER | Non-Final OA | TORAY INDUSTRIES, INC. |
| 17910522 | MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCER | Non-Final OA | TORAY INDUSTRIES, INC. |
| 17907313 | INDUCING PRODUCTION OF ANTI-OLIGOMANNOSE ANTIBODIES | Non-Final OA | SRI International |
| 18204412 | COMPLEX OF MUTUALISTIC MICROBES DESIGNED TO INCREASE PLANT PRODUCTIVITY | Final Rejection | UT-Battelle, LLC |
| 18563440 | ANTIBODIES | Non-Final OA | Oxford University Innovation Limited |
| 18565805 | CAR-T CELL THERAPY FOR TRIPLE NEGATIVE BREAST CANCER | Non-Final OA | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. |
| 18224345 | NON-PROTEIN PHENYLALANINE ANALOGUES FOR INHIBITING CYANOBACTERIA AND PLANT GROWTH | Final Rejection | YEDA RESEARCH AND DEVELOPMENT CO. LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy